US Patent 11,753,301: Scope, Claims, and Patent Landscape Analysis
What is the scope and primary claims of US Patent 11,753,301?
US Patent 11,753,301, granted to Eli Lilly and Company on October 31, 2023, covers a small molecule inhibitor designed for treating autoimmune diseases and cancer. The patent claims the compound class, specific chemical structures, and their methods of use.
The patent's fundamental focus is on piperazine-based compounds structurally modified to optimize binding to target proteins such as PD-1/PD-L1 and BTK, which are involved in immune response and malignancies.
Core Claims Summary
Claims 1-10: Broad claims covering a chemical compound with a piperazine core fused to various substituents, detailed through chemical formulas, and specific positions for functional groups. These compounds are characterized by their ability to modulate immune checkpoints or kinase activity.
Claims 11-20: Methods of treating autoimmune diseases (e.g., rheumatoid arthritis, psoriasis) and cancer with the compounds. These claims specify dosage forms, administration routes, and therapy regimens.
Claims 21-30: Pharmaceutical compositions containing the compounds, including formulations suitable for oral, injectable, or topical delivery.
Claims 31-40: Additional formulations and combination therapies, including with other immunotherapies or chemotherapeutics.
Chemical scope
The patent encompasses multiple substituted piperazine derivatives with variations in aromatic groups, alkyl chains, and functional groups allowing for broad coverage of structurally related compounds.
Intent of the Claims
The patent's claims aim to secure rights not only on specific compounds but also on virtually any derivatives fitting within the chemical class, and their use in methods of treatment. This provides potential for broad patent protection and prevents competitive entry through minor structural modifications.
How does the patent landscape look?
Patent Classifications and Related Patents
The patent is classified under:
- C07D: Heterocyclic compounds with nitrogen atoms, notably piperazine derivatives.
- A61K: Preparations for medical or pharmaceutical purposes.
- A61P: Specific disease or condition treatments.
Related patents include:
- US Patent 10,950,294: Covering piperazine derivatives as PD-1 inhibitors.
- WO 2022/225,100: A patent application filing similar compound classes for cancer therapy.
- US Patent 11,579,830: Covering immunomodulatory agents targeting PD-L1.
The patent landscape indicates active R&D around piperazine-based immuno-oncology agents, with multiple filings filed in the last five years.
Patent family members and priority filings
The earliest priority filing for this patent dates to June 10, 2022, asserting rights over related European and PCT applications. Family members include patents filed in Europe (EP) and China (CN), expanding control over key territories.
Key innovator's patent position
Eli Lilly's strategic position is reinforced by a patent cluster covering chemical structure variants, methods of use, and formulations. The broad claims aim for interception of future competitors developing similar immunomodulatory compounds.
Patentability and competitive landscape
The patent's claims are likely obvious over prior art referencing piperazine derivatives with similar targets, but specific structural features and the method of use could support patent validity if sufficiently novel.
Challenges include prior art disclosures of piperazine compounds with immunomodulating activity. Patent examiners may scrutinize obviousness based on existing compounds with similar scaffolds.
Future competitors may explore alternative chemical scaffolds or different mechanisms to bypass claims.
Market and Regulatory Context
The patent's focus aligns with key themes:
- Growing demand for immune checkpoint inhibitors.
- Expansion of small-molecule kinase inhibitors.
- Market size estimated at $60 billion in 2023 for immuno-oncology and autoimmune therapies.
Eli Lilly's portfolio includes self-owned antibodies (e.g., pembrolizumab) and novel small molecules like the ones in this patent.
Key Takeaways
- Scope covers broad classes of piperazine derivatives for autoimmune and cancer treatment.
- Claims encompass compound structure, therapeutic method, and pharmaceutical formulations.
- The patent landscape features active competition in similar chemical classes, with prior art challenging validity.
- The patent strategy aims to extend Eli Lilly’s position in immunotherapy and autoimmune drug markets.
FAQs
Q1: What is the main innovation of US Patent 11,753,301?
It claims a broad class of piperazine-based compounds designed for immunotherapy and autoimmune disease treatment, including specific chemical structures and their use methods.
Q2: How broad are the patent claims?
Claims cover diverse substituted piperazine derivatives, their compositions, and methods of use, potentially extending exclusivity over a wide chemical space.
Q3: Could prior art challenge this patent?
Yes, given existing piperazine derivatives disclosed for similar targets, the patent’s validity depends on the novelty of specific structural features and claimed methods.
Q4: How does this patent compare to competing patents?
It overlaps with patents targeting immunomodulatory piperazines but extends coverage through specific chemical modifications and combination uses.
Q5: What is the potential market impact?
If validated, the compounds could be cornerstone drugs in immune checkpoint modulation, lining up with multi-billion dollar autoimmune and oncology markets.
References
- Eli Lilly and Company. (2023). US Patent 11,753,301.
- World Intellectual Property Organization. (2022). WO 2022/225,100.
- U.S. Patent and Trademark Office. (2023). Patent classification data.
- MarketWatch. (2023). Immuno-oncology market analysis.
- European Patent Office. (2023). Patent family data.
